Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Patients with non-Hodgkin's lymphomas are classified by the Working Formulation into low, intermediate, and high grade based on the aggressiveness of the lymphoma. Intermediate- and high-grade lymphomas are rapidly progressive, fatal diseases unless the patient achieves a complete remission after treatment with combination chemotherapy. Complete remissions have been reported in 40% to 80% of these patients, and 30% to 60% of these patients are actually cured. alpha-Interferon studies of relapsed patients have resulted in approximately a 15% objective response rate with only 2% complete remissions. Thus at this time alpha-interferon has no role in the treatment of these patients. Treatment of low-grade lymphomas with combination chemotherapy results in complete remission rates varying from 25% to 70%. However, these complete remissions are not durable and the patients essentially all relapse with a 22-month median duration of complete remission. In spite of these relapses, median survival for all patients exceeds 7 years. alpha-Interferon has shown beneficial clinical activity in the low-grade lymphomas. Overall response rates are approximately 46%, with 11% complete remission. There is some evidence to suggest that there is a useful dose-response curve, with the highest remission rates being seen at the highest alpha-interferon doses. The median duration of response is approximately 8 months. Combining alpha-interferon with standard chemotherapy has not resulted in an easily detectable improvement in response rate or duration. The role of alpha-interferon in prolonging remission duration for these low-grade lymphomas is being investigated by the Southwest Oncology Group. In summary, alpha-interferon has shown moderate activity when used to treat patients with low-grade non-Hodgkin's lymphomas.
 ...
PMID:Clinical trials of alpha-interferon in the treatment of non-Hodgkin's lymphoma. 194 24

One hundred thirty-two cases diagnosed as non-Hodgkin's lymphoma (NHL) by fine-needle aspiration cytology (FNAC) and histology, and 43 cases in which there were minor or major discrepancies between cytology and histology for diagnosis of NHL, were reviewed. The diagnostic accuracy of FNAC for NHL was 86.3% at the initial diagnosis. Following review, all the 132 cases initially diagnosed as NHL by cytology and histology remained so with minor changes in subtypes in a few cases. Of the 43 discrepant cases, 28 turned out to be NHL and 6 as Hodgkin's disease (HD); 3 were anaplastic carcinoma; and in 6 cases the discrepancy still persisted. Diagnostic accuracy of FNA for NHL improved to 98.0% following review. Categorization of histologically diagnosed NHL cases under working formulation showed that 10.4%, 21.5%, and 57.7%, respectively, were low, intermediate, and high-grade lymphomas. The corresponding figures were 16.6%, 18.4%, and 60.1%, respectively, in cytology. The diagnostic accuracy of cytology for subtyping was found to be 67.5%.
 ...
PMID:FNA cytodiagnosis of non-Hodgkin's lymphoma and its subtyping under working formulation of 175 cases. 195 27

Cell size and mitotic indices were studied in 243 non-Hodgkin's lymphomas (NHL) diagnosed cytologically and classified according to the Working Formulation. Low-, intermediate-, and high-grade lymphomas constituted 14.8%, 18.9%, and 61.7% of the cases, respectively. Measurement of the diameter of 100 lymphoid cells in each case showed that in most of the low-grade malignant lymphomas, 50-80% of the cells were small (less than 10 microns). A majority of the cells (an average of 45-60%) in intermediate- and high-grade lymphomas were in the range of 11-15 microns. Only the intermediate-grade large noncleaved and high-grade immunoblastic lymphomas had a majority of their cells (greater than 50%) larger than 15 microns. The mitotic indices (number of mitotic figures per 500 lymphoid cells) showed a highly significant difference between low- (0.7 +/- 1.14), intermediate- (3.0 +/- 2.67), and high-grade (5.4 +/- 3.40) lymphomas using the Wilcoxon's signed rank test (P less than 0.0001). Nearly two-thirds of the cases in each grade were within specific ranges of mitotic indices, i.e., less than 1 for low-, 1-3 for intermediate-, and greater than 3 for high-grade lymphomas.
 ...
PMID:Working formulation of the non-Hodgkin's lymphomas: a study of cell size and mitotic indices in cytologic subtypes. 195 28

Modern high-dose therapy with autologous bone marrow transplantation (ABMT) used for the management of Hodgkin's disease (HD) and non-Hodgkin's lymphomas (NHL) began about a decade ago. As more lymphoma patients are treated and followed for longer periods of time, the value of this procedure is becoming clearer. ABMT for low grade NHL has not been studied extensively and follow-up is too short to demonstrate definite efficacy, but initial reports have suggested advanced low-grade NHL might be eradicated for some patients. More than a third of patients with intermediate- and high-grade lymphomas that are refractory to standard therapy or demonstrate poor prognostic factors, when treated with high-dose therapy and ABMT, experience long-term, disease-free survival. About 30% of patients with Hodgkin's disease that was not eradicated with conventional therapy experience long-term, disease-free survival when treated with high-dose therapy and ABMT. Patients who cannot have ABMT because of some bone marrow abnormality, can be offered high-dose therapy and restoration of marrow function by transplantation of hematopoietic stem cells collected from the peripheral blood rather than the marrow with no increased risk of failure to achieve long-term, disease-free survival. Continued efforts to reduce the morbidity and mortality associated with high-dose therapy, to identify the optimal high-dose therapy for each histologic type of lymphoma, and to better identify those patients most likely to benefit will improve the value of high-dose therapy and ABMT.
 ...
PMID:Autologous bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. 197 1

In a prospective study of 42 high-grade lymphomas which were categorized according to the Kiel classification, the clinical significance of immune genotyping was studied. Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements were investigated. In 33 cases the immune genotype confirmed the phenotype. In one case with equivocal phenotype a TCR beta-chain rearrangement proved the T-cell origin of the lymphoma. None of the cases showed a bigenotype. There were eight lymphomas with immunoglobulin and TCR beta-chain and gamma-chain genes in germline configuration, which were divided into a group of immature lymphomas and a group of lymphomas with a more mature phenotype. The immature lymphomas had widespread disease, rapid progression, and favorable prognosis after intensive chemotherapy. The group of T-cell and Ki-1 lymphomas with null-cell genotype was clinically heterogeneous. Three of four cases were secondary lymphomas after lymphomatoid papulosis, lymphomatoid granulomatosis, or Hodgkin's disease. All cases presented with extranodal involvement. Only one of these patients is in continuous remission. In conclusion, the lack of immunoglobulin and TCR beta-chain and gamma-chain gene rearrangements does not exclude the diagnosis of high-grade malignant lymphoma, especially in cases with unusual extranodal involvement. However, the DNA analysis identifies a null-cell genotype subset of high-grade lymphomas which may have clinical significance.
 ...
PMID:Clinical characteristics of high-grade lymphomas with immune genes in germline configuration. 198 55

High-grade B-cell non-Hodgkin's lymphomas are observed in 5% to 10% of patients with acquired immunodeficiency syndrome. To describe their histologic subtypes, a group of pathologists was formed. One hundred thirteen cases were reviewed and classified according to the Working Formulation, the updated Kiel classification, and a recent description of morphologic variants of high-grade B-cell non-Hodgkin's lymphoma. Three major types of intermediate- or high-grade lymphomas were observed: (1) large-cell or centroblastic mainly polymorphic lymphomas with a component of immunoblasts (35 cases); (2) immunoblastic lymphomas with plasmablastic and plasmacytic features in most cases (33 cases); and (3) small non-cleaved cell Burkitt's or non-Burkitt's lymphoma (41 cases), with 15 cases fitting typical criteria of Burkitt's lymphoma and 26 heterogeneous cases in which the size and shape of the cells and the presence of plasmablastic features varied. The most frequent pathologic sites of involvement at presentation were the lymph nodes, gastrointestinal tract, bone marrow, brain, oral cavity, and muscles. A comparison between the histologic type and the site of involvement showed that most cases involving lymph nodes, bone marrow, or muscles were small noncleaved cell Burkitt's or non-Burkitt's lymphomas, while those that affected the gastrointestinal tract, brain, and oral cavity were centroblastic or immunoblastic lymphomas with consistent plasmacytic differentiation. In 10 cases, previous persistent generalized lymphadenopathy syndrome was present. In 13 cases, the lymphomatous proliferation was associated with follicular or diffuse hyperplasia seen on the same lymph node biopsy specimen or in another lymph node.
 ...
PMID:Histopathologic features of high-grade non-Hodgkin's lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. 198 8

Transmission electron microscopy was used to study the ultrastructure of nucleoli in seven high- and seven low-grade non-Hodgkin's lymphomas. Nucleoli with a single large fibrillar centre were predominantly seen in the low-grade group, while the majority of nucleoli in high-grade lesions contained several small fibrillar centres of approximately equal size. A third type of nucleolar appearance was identified, with a large central fibrillar centre surrounded by numerous small 'satellite' fibrillar centres. This nucleolar configuration was the least common but was more often seen in low-grade than in high-grade lymphomas. The mean fibrillar centre cross-sectional area was determined for each group and measured 278,800 nm2 for low-grade non-Hodgkin's lymphomas and 62,507 nm2 for high-grade lymphomas (P less than 0.001). These results show that fibrillar centre size and morphology correlates with grade of non-Hodgkin's lymphoma and may reflect differences in ribosomal deoxyribonucleic acid transcription.
 ...
PMID:Nucleolar ultrastructure in low- and high-grade non-Hodgkin's lymphomas. 201 26

The CD30 antigen has been reported as the immunophenotypic hallmark of a recently described category of non-Hodgkin's lymphoma, termed anaplastic large cell lymphoma. From a series of approximately 500 lymphomas, 17 cases showing typical anaplastic features have been identified. They were strongly labelled by monoclonal antibodies recognizing CD30 (Ki-1 or BerH2). However, 36 other lymphomas, mainly high-grade, of non-anaplastic cytology also expressed CD30, either diffusely or focally, with a staining pattern identical to that seen in anaplastic large cell lymphomas. This clearly suggests that such lymphomas cannot be identified solely on the basis of being high-grade non-Hodgkin's lymphomas showing CD30 positivity. From the present results, the distinction between the anaplastic and non-anaplastic types would be better made with antibodies to epithelial membrane antigen than to CD30. Clinical data, available for 48 of the patients (16 with anaplastic large cell lymphomas and 32 with non-anaplastic) revealed no significant differences with regard to age at presentation, sex or clinical signs. A short-term follow-up study of 25 patients revealed that for the first 2 years after diagnosis there were no significant differences in patient survival between anaplastic large cell lymphoma, other CD30+ high-grade lymphomas and all high-grade non-Hodgkin's lymphomas considered together. These findings, which must be confirmed by larger studies, suggest that in a general lymphoma clinic there is probably little justification for differentiating anaplastic large cell lymphomas or CD30+ lymphomas from other high-grade non-Hodgkin's lymphomas.
 ...
PMID:CD30 expression in non-Hodgkin's lymphoma. 217 74

Twenty-six cases of high-grade lymphomas with activation markers (CD30) classified and immunophenotyped according to the Kiel classification were studied to determine their fine structural features. Transmission electron microscopy showed in 17 cases anaplastic nuclear and cytoplasmic changes identical to those observed in Hodgkin's disease, it being impossible to determine by the morphology a B, T, or null nature. Four high-grade B-centroblastic and immunoblastic cases and five T-pleomorphic cases showed nuclear changes and cytoplasmic differentiation that suggested a T or B nature. An immunogold-labeling technique showed CD30-positive particles primarily in the Golgi complex and occasionally in the cell membrane.
 ...
PMID:Ultrastructure of 26 cases of Ki-1 lymphomas: morphoimmunologic correlation. 217 95

The present study was undertaken to establish the incidence of t(14;18) (q32:q21) chromosomal translocations detectable by a polymerase chain reaction (PCR) assay on fixed lymphoma biopsies. DNA samples from 113 formalin-fixed, paraffin-embedded tissue biopsies (non-Hodgkin's lymphomas, 96 cases; Hodgkin's disease, six cases; reactive, 11 cases) were amplified by the PCR. Of the 96 non-Hodgkin's lymphoma cases, 56 had a follicular pattern and 40 had a diffuse pattern. Polymerase chain reaction-amplifiable t(14;18) chromosomal translocations were detected in 23 of 43 follicular low-grade lymphomas, one of eight follicular intermediate grade lymphomas, one of five follicular high-grade lymphomas, and one of 10 diffuse large-cell lymphomas. The remaining 30 diffuse lymphomas represented the spectrum of the Working Formulation classification. There were six biopsy specimens of Hodgkin's disease and 11 biopsy specimens of follicular hyperplasia; all were negative. The translocation was not detected in 16 biopsies (non-Hodgkin's lymphomas, seven cases; follicular hyperplasia, nine cases) from patients infected with the human immunodeficiency virus. Since this procedure uses the widely available fixed paraffin-embedded material, correlative studies between histology and genetic aberrations can be readily undertaken.
 ...
PMID:Detection of specific t(14;18) chromosomal translocations in fixed tissues. 230 46


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>